Medicamen Biotech Ltd-$
Medicamen Biotech Ltd-$ (MEDICAMEQ) last reported results for the quarter ended Jun 2026, with sales of ₹47.9 crore and net profit of ₹1.85 crore. The stock last traded at ₹319, a market capitalisation of ₹433 crore, on a P/E of 39.9. Over the past 52 weeks the stock has ranged between ₹210 and ₹454. Figures are as of 6 Oct 2026 and are not real time.
Medicamen Biotech Ltd-$ share price and key metrics
- Current price
- ₹319
- Market cap
- ₹433 cr
- Stock P/E
- 39.9
- Book value
- ₹203
- ROE
- 3.95%
- ROCE
- 5.82%
- Dividend yield
- 0.31%
- 52w high / low
- 454/210
Metrics as of 6 Oct 2026. Not real time.
Track Medicamen Biotech Ltd-$
Cruxal reads every Medicamen Biotech Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Medicamen Biotech Ltd-$ growth and returns
- 10 Years
- %
- 5 Years
- 12%
- 3 Years
- 12%
- TTM
- 25%
- 10 Years
- %
- 5 Years
- -4%
- 3 Years
- -13%
- TTM
- 14%
- 10 Years
- 2%
- 5 Years
- -12%
- 3 Years
- -22%
- 1 Year
- 2%
- 10 Years
- %
- 5 Years
- 6%
- 3 Years
- 4%
- Last Year
- 4%
Medicamen Biotech Ltd-$ quarterly results
In the quarter ended Jun 2026, sales were ₹47.9 cr, up 11.3% from ₹43.04 cr a year earlier. Net profit was ₹1.85 cr, up 15.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 44.74 | 45.14 | 29.61 | 43.04 | 47.17 | 46.91 | 60.65 | 47.9 |
| Expenses | 39.43 | 38.43 | 31.22 | 38.43 | 42.01 | 42.53 | 55.22 | 43.57 |
| Operating profit | 5.31 | 6.71 | -1.61 | 4.61 | 5.16 | 4.38 | 5.43 | 4.33 |
| OPM % | 11.87% | 14.86% | -5.44% | 10.71% | 10.94% | 9.34% | 8.95% | 9.04% |
| Other income | 0.29 | 0.14 | 5.23 | 0.47 | 0.37 | 0.53 | 1.74 | 0.86 |
| Interest | 1.04 | 0.76 | 0.65 | 1.15 | 0.99 | 0.97 | 0.38 | 0.83 |
| Depreciation | 2.61 | 2.21 | 0.48 | 1.8 | 1.86 | 1.83 | 1.73 | 1.79 |
| Profit before tax | 1.95 | 3.88 | 2.49 | 2.13 | 2.68 | 2.11 | 5.06 | 2.57 |
| Tax % | 53.85% | 24.74% | 25.30% | 24.88% | 21.27% | 22.27% | 12.06% | 28.40% |
| Net profit | 0.91 | 2.92 | 1.87 | 1.6 | 2.12 | 1.64 | 4.45 | 1.85 |
| EPS (₹) | 1.15 | 2.73 | 1.90 | 1.59 | 1.97 | 1.61 | 2.85 | 1.56 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Medicamen Biotech Ltd-$ annual results
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 125 | 113 | 115 | 141 | 179 | 163 | 198 | 203 |
| Operating profit | 17 | 20 | 20 | 24 | 24 | 24 | 14 | 21 | 19 |
| OPM % | 14% | 16% | 17% | 21% | 17% | 13% | 9% | 10% | 10% |
| Net profit | 12 | 13 | 12 | 15 | 15 | 9 | 7 | 10 | 10 |
| EPS (₹) | 10.28 | 10.88 | 9.93 | 12.20 | 11.73 | 8.60 | 5.59 | 7.11 | 7.99 |
TTM is the trailing twelve months to the most recent quarter.
Medicamen Biotech Ltd-$ balance sheet
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 14 |
| Reserves | 75 | 109 | 121 | 134 | 181 | 194 | 200 | 262 |
| Borrowings | 12 | 11 | 19 | 26 | 26 | 31 | 34 | 49 |
| Other liabilities | 38 | 49 | 42 | 53 | 59 | 56 | 50 | 47 |
| Total liabilities | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 |
| Fixed assets | 24 | 34 | 90 | 92 | 93 | 92 | 87 | 85 |
| CWIP | 15 | 40 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 97 | 107 | 104 | 133 | 186 | 203 | 210 | 287 |
| Total assets | 137 | 181 | 194 | 226 | 279 | 295 | 297 | 372 |
As reported by the company. Total assets equal total liabilities by construction.
Medicamen Biotech Ltd-$ cash flow
| ₹ crore | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 4 | 13 | 13 | 4 | -6 | -7 | -8 | -33 |
| Cash from investing | -15 | -37 | -18 | -8 | -6 | -6 | -1 | -3 |
| Cash from financing | -4 | 19 | 6 | 4 | 29 | 6 | -1 | 64 |
| Net cash flow | -14 | -5 | 1 | -0 | 17 | -6 | -11 | 28 |
| Free cash flow | -11 | -25 | -5 | -4 | -13 | -13 | -10 | -38 |
| CFO / operating profit | 48% | 88% | 88% | 30% | -13% | -16% | -47% | -150% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Medicamen Biotech Ltd-$ operating ratios
| Per year | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | — | 16% | 13% | 12% | 10% | 8% | 6% | 6% |
| Debtor days | 129 | 145 | 170 | 200 | 169 | 112 | 155 | 151 |
| Inventory days | 67 | 78 | 27 | 188 | 228 | 234 | 268 | 251 |
| Days payable | 134 | 173 | 169 | 302 | 241 | 154 | 184 | 144 |
| Cash conversion cycle | 62 | 51 | 28 | 86 | 156 | 193 | 239 | 259 |
| Working capital days | 116 | 130 | 126 | 147 | 156 | 123 | 186 | 193 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Medicamen Biotech Ltd-$ shareholding pattern
Promoters held 40.46% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.07% and DIIs 0.40%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 42.99% | 42.99% | 43.16% | 40.46% | 40.46% | 40.46% | 40.46% | 40.46% |
| FIIs | 0.06% | 0.06% | 0.12% | 0.00% | 0.05% | 0.02% | 0.10% | 0.07% |
| DIIs | 1.17% | 0.87% | 0.69% | 0.64% | 0.59% | 0.44% | 0.00% | 0.40% |
| Government | 0.00% | 0.06% | 0.06% | 0.05% | 0.05% | 0.05% | 0.05% | 0.05% |
| Public | 55.79% | 56.04% | 55.99% | 58.83% | 58.84% | 59.02% | 59.39% | 59.01% |
| No. of shareholders | 10,792 | 10,576 | 10,435 | 10,808 | 11,177 | 10,967 | 10,806 | 11,047 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Medicamen Biotech Ltd-$ corporate filings
- Medicamen Biotech Ltd. announces trading plan under SEBI (PIT) Regulations 2015 for Mr. Sanjay Bansal on 30 September 2026Company Updatelow impact
Cruxal's analysis: The company has disclosed a trading plan for Mr. Sanjay Bansal, effective from 30…
Read the full analysis - Medicamen Biotech Limited concludes 33rd AGM; shareholders approve financial statements, dividend, and related party transactionsCompany Updatelow impact
Cruxal's analysis: Medicamen Biotech Limited has successfully concluded its 33rd Annual General Meeting held…
Read the full analysis - Closure of Trading Window- Septemeber 30, 2026Insider Trading / SASTlow impact
- Medicamen Biotech Limited concludes 33rd Annual General Meeting; shareholders vote on financial adoption and related party transactionsAGM/EGMlow impact
Cruxal's analysis: Medicamen Biotech Limited has successfully concluded its 33rd Annual General Meeting held…
Read the full analysis - Medicamen Biotech Limited Announces 33rd Annual General Meeting and Dividend DeclarationCompany Updatelow impact
Cruxal's analysis: Medicamen Biotech Limited has issued a formal notice for its 33rd Annual General Meeting…
Read the full analysis - Medicamen Biotech Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Medicamen Biotech Ltd has submitted its Annual Report in compliance with Regulation 34(1)…
Read the full analysis - Medicamen Biotech Ltd files Business Responsibility and Sustainability Report (BRSR) for 2025-26Otherslow impact
Cruxal's analysis: Medicamen Biotech Ltd has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Medicamen Biotech Limited Announces 33rd AGM and Releases Integrated Annual Report for FY 2025-26AGM/EGMhigh impact
Cruxal's analysis: Medicamen Biotech Limited has scheduled its 33rd Annual General Meeting for September 26…
Read the full analysis - Medicamen Biotech Limited Announces Book Closure and Record Date for 33rd Annual General Meeting and Final DividendCorp. Actionlow impact
Cruxal's analysis: Medicamen Biotech Limited has formally notified the stock exchanges that its Register of…
Read the full analysis - Medicamen Biotech Limited Announces Publication of Un-audited Financial Results for Quarter Ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Medicamen Biotech Limited has formally published its un-audited standalone and…
Read the full analysis - Medicamen Biotech Ltd announces book closure for final dividend of Rs 1 per shareCorp. Actionlow impact
Cruxal's analysis: Medicamen Biotech Ltd has scheduled the closure of its Register of Members and Share…
Read the full analysis - Medicamen Biotech Limited Reports Q1 FY27 Financial Results and Announces Final Dividend of INR 1 per ShareResultmedium impact
Cruxal's analysis: Medicamen Biotech Limited reported Q1 FY27 standalone revenue of INR 43.85 crore and a…
Read the full analysis - Medicamen Biotech Limited schedules Board Meeting for August 14, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Medicamen Biotech Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.